Standard Glass Lining Technology Limited’s Initial Public
Offering to open on Monday, January 6, 2024, price band set at ₹133/- to ₹140/-
per Equity Share
Mumbai, December 31, 2024: Standard Glass Lining Technology Limited is one of the top five
specialized engineering equipment manufacturers for the pharmaceutical and
chemical sectors in India, in terms of revenue in Fiscal 2024, it has fixed the
price band of ₹133/- to ₹140/- per Equity Share of face value ₹10/- each
for its maiden initial public offer.
The Initial Public Offering (“IPO” or “Offer”)
of the Company will open on Monday, January 6, 2024, for subscription and
close on Wednesday,
January 8, 2024. Investors can bid for a minimum of 107 Equity
Shares and in multiples of 107 Equity Shares thereafter.
The IPO is a mix of fresh issues of up to Rs 210 crore and an
offer of sale of up to 1,42,89,367 equity shares by Promoter Selling and
Promoter Group and Other Selling Shareholders.
The proceeds from its fresh issuance to the extent of Rs 10
crore will be utilized for funding of capital expenditure requirements of the
Company towards the purchase of machinery and equipment; Rs 130 crore for
repayment or prepayment, in full or in part, of all or a portion of certain
outstanding borrowings availed by the Company and investment in its wholly
owned Material Subsidiary, S2 Engineering Industry Private Limited, for
repayment or prepayment, in full or in part, of all or a portion of certain
Outstanding borrowings availed by S2 Engineering Industry Private Limited, from
banks and financial institutions; Rs 30 crore for Investment in its wholly
owned Material Subsidiary, S2 Engineering Industry Private Limited, for funding
its capital expenditure requirements towards the purchase of machinery and
equipment; Rs 20 crore for funding inorganic growth through strategic
investments and/or acquisitions; and general corporate purposes.
Standard Glass Lining Technology’s capabilities include designing,
engineering, manufacturing, assembly, installation, and commissioning solutions
and establishing standard operating procedures for pharmaceutical and chemical
manufacturers on a turnkey basis. Its portfolio comprises core equipment used
in the manufacturing of pharmaceutical and chemical products, which can be
categorized into: Reaction Systems; Storage, Separation, and Drying Systems;
and Plant, Engineering, and Services (including other ancillary parts). It is
also one of India’s top three manufacturers of glass-lined, stainless steel,
and nickel alloy-based specialized engineering equipment, in terms of revenue
in Fiscal 2024, according to an F&S Report. It is also one of the top three
suppliers of polytetrafluoroethylene (“PTFE”) lined pipelines and fittings in
India, in terms of revenue in Fiscal 2024. It has been the fastest-growing
company in the industry, and it has operated during the past three completed
fiscals in terms of revenue.
The company possesses in-house capabilities to manufacture all
the core specialized engineering equipment required in the active
pharmaceutical ingredient (“API”) and fine chemical products manufacturing
process. Over the last decade, it has supplied over 11,000 products. Its
marquee customer base includes 30 out of approximately 80 pharmaceutical and
chemical companies in the NSE 500 index as of June 30, 2024. It operates
through its eight manufacturing facilities spread across a built-up/floor area
of over 400,000 sq. ft., strategically located in Hyderabad, Telangana, the
“Pharma Hub” of India, which accounted for 40.00% of the total Indian bulk drug
production in Fiscal 2024.
IIFL Capital Services Limited, and Motilal Oswal Investment
Advisors Limited are the book-running lead managers, and KFin Technologies Limited
is the registrar of the issue.
The Offer is being made through the book-building process,
wherein not more than 50% of the offer shall be available for allocation on a
proportionate basis to qualified institutional buyers, not less than 15% of the
offer shall be available for allocation to non-institutional investors, and not
less than 35% of the offer shall be available for allocation to retail
individual bidders.
Notes for
Reference:
Issue Size
of the IPO based on the upper and lower end of the price band
|
Fresh
Issue |
OFS (1,42,89,367 equity shares) |
Total |
Lower
Band (@Rs 133) |
Rs 210
crore |
Rs 190.05
crore |
Rs 400.05 crore |
Upper
Band (@Rs 140) |
Rs 210
crore |
Rs 200.05
crore |
Rs 410.05 crore |
No comments:
Post a Comment